Children with unilateral cerebral palsy (CP) show less effective use of the affected upper limb from age 9 and up despite improvements in grip strength and hand function, according to a five-year study. The research, “Time Course of Upper Limb Function in Children with Unilateral Cerebral Palsy:…
Botox (Dysport) injections in lower leg muscles improve muscle tone, movement and gait in children with spastic cerebral palsy and lasts up to three months, regardless of the number of treatment sessions, a new study shows. The study, “Effectiveness of multiple botulinum toxin sessions and the duration…
Risperidone is a well-tolerated and efficient therapy to help manage motor symptoms in children with choreoathetoid cerebral palsy, according to researchers. Their study, “Effect of Risperidone on the Motor and Functional Disability in Children With Choreoathetoid Cerebral Palsy,” was published in the journal Pediatric Neurology. Children…
A single injection of Dysport (abobotulinumtoxinA) is safe and effective in treating lower limb spasticity due to cerebral palsy in children across different age groups, according to a pooled analysis from four clinical trials. Ipsen Biopharmaceuticals presented these results during the 2018 Annual Meeting of the…
Using a range of measures to assess cerebral palsy patients’ twitching, then adjusting the treatment to the patient, is better than giving each a commonly used standard or high dose, a study reports. Twitching, or spasticity, is a common feature of many neurological diseases. It causes movement problems, saps a…
Dysport Therapeutic has been approved by Health Canada for the treatment of spasticity affecting the lower limbs in adults, which could be of enormous benefit for patients with conditions such as cerebral palsy. The approval was announced in a press release by Ipsen Biopharmaceuticals Canada Inc. Spasticity is…
Dysport (abobotulinumtoxin A) administered at a dose two times higher than that of Botox (onabotulinumtoxin A) is a cost-effective option to treat children with cerebral palsy, a study shows. Published in the European Journal of Pediatric Neurology, a prospective, real-world study showed Dysport, when given at a two-fold higher unit…
Injections of botulinum toxin type A (BoNT-A) cause more frequent systemic adverse events in children with severe cerebral palsy than in those who have milder disease. That finding may warrant consideration of treatment risks by clinicians and families, according to a recent study. The research, “Severity of cerebral…
A drop in muscle strength may be the driver of the fast decline observed in motor capacity in cerebral palsy patients, researchers found. The study, “Functional capacity in adults with cerebral palsy: Lower limb muscle strength matters,” was published in the…
The use of botulinum toxin A in children with cerebral palsy (CP) differs according to their age, sex, and gross motor function, according to a new Swedish study. The study, “Treatment with Botulinum toxin A in a total population of children with cerebral palsy – a…